Optimizing immunotherapy for neuroblastoma

Neuroblastoma is a pediatric tumor of the sympathic nervous system⁠. The immunontherapy Dinutuximab against GD2 has led to a small increase in the survival of patients with high-risk neuroblastoma⁠. Therefore, immunotherapies are promising treatment strategies for neuroblastoma⁠.

In this project we will investigate immunosuppressive factors in the tumor microenvironment and tumor specific targets in order to improve immunotherapies for neuroblastoma, including B7H3 CAR-T cells and anti-GD2 immunotherapy⁠.

Anne Borst